search
Back to results

A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.

Primary Purpose

Parkinson Disease

Status
Completed
Phase
Phase 2
Locations
Japan
Study Type
Interventional
Intervention
KDT-3594
Pramipexole
Sponsored by
Kissei Pharmaceutical Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Parkinson Disease

Eligibility Criteria

20 Years - 79 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Japanese patients
  • Patients who are diagnosed with Parkinson's disease according to UK Parkinson's Disease society brain bank clinical diagnostic criteria
  • Patients with Parkinson's disease in Stages 1 to 3 on the Modified Hoehn and Yahr Scale

Exclusion Criteria:

  • Patients who are suspected any parkinsonism except for idiopathic Parkinson's disease
  • Patients who underwent neurosurgical treatment (stereotaxic destruction, deep brain stimulation etc.) for PD, or patients for whom surgical treatment is scheduled during the study
  • Patients with a complication of obvious dementia, or patients with Mini-Mental State Examination (MMSE) score < 24 points

Sites / Locations

  • Research Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

KDT-3594

Pramipexole

Arm Description

Reference drug

Outcomes

Primary Outcome Measures

Change in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) score
Change from baseline (Week 0) in MDS-UPDRS total score

Secondary Outcome Measures

Change in Parkinson's Disease Questionnaire-39 (PDQ-39) score
Change from baseline (Week 0) in PDQ-39 summary index score
Change in Parkinson's Disease Sleep Scale-2 (PDSS-2) score
Change from baseline (Week 0) in PDSS-2 total score

Full Information

First Posted
February 15, 2019
Last Updated
February 16, 2021
Sponsor
Kissei Pharmaceutical Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT03845387
Brief Title
A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.
Official Title
A Phase II Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.
Study Type
Interventional

2. Study Status

Record Verification Date
February 2021
Overall Recruitment Status
Completed
Study Start Date
February 26, 2019 (Actual)
Primary Completion Date
February 21, 2020 (Actual)
Study Completion Date
February 21, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Kissei Pharmaceutical Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Objective of this study is to investigate the efficacy, safety and pharmacokinetics of KDT-3594 in patients with early Parkinson's disease without a concomitant medication of L-dopa.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinson Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
74 (Actual)

8. Arms, Groups, and Interventions

Arm Title
KDT-3594
Arm Type
Experimental
Arm Title
Pramipexole
Arm Type
Other
Arm Description
Reference drug
Intervention Type
Drug
Intervention Name(s)
KDT-3594
Intervention Description
oral administration, dose titration
Intervention Type
Drug
Intervention Name(s)
Pramipexole
Intervention Description
ER formulation, oral administration, dose titration
Primary Outcome Measure Information:
Title
Change in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) score
Description
Change from baseline (Week 0) in MDS-UPDRS total score
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Change in Parkinson's Disease Questionnaire-39 (PDQ-39) score
Description
Change from baseline (Week 0) in PDQ-39 summary index score
Time Frame
12 weeks
Title
Change in Parkinson's Disease Sleep Scale-2 (PDSS-2) score
Description
Change from baseline (Week 0) in PDSS-2 total score
Time Frame
12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
79 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Japanese patients Patients who are diagnosed with Parkinson's disease according to UK Parkinson's Disease society brain bank clinical diagnostic criteria Patients with Parkinson's disease in Stages 1 to 3 on the Modified Hoehn and Yahr Scale Exclusion Criteria: Patients who are suspected any parkinsonism except for idiopathic Parkinson's disease Patients who underwent neurosurgical treatment (stereotaxic destruction, deep brain stimulation etc.) for PD, or patients for whom surgical treatment is scheduled during the study Patients with a complication of obvious dementia, or patients with Mini-Mental State Examination (MMSE) score < 24 points
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Naomi Koshihara
Organizational Affiliation
Kissei Pharmaceutical Co., Ltd.
Official's Role
Study Director
Facility Information:
Facility Name
Research Site
City
Multiple Locations
Country
Japan

12. IPD Sharing Statement

Learn more about this trial

A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.

We'll reach out to this number within 24 hrs